Search details
1.
Excluded versus included patients in a randomized controlled trial of infections caused by carbapenem-resistant Gram-negative bacteria: relevance to external validity.
BMC Infect Dis
; 21(1): 309, 2021 Mar 31.
Article
in English
| MEDLINE | ID: mdl-33789574
2.
Epidemiology of Mucormycosis in Greece; Results from a Nationwide Prospective Survey and Published Case Reports.
J Fungi (Basel)
; 9(4)2023 Mar 29.
Article
in English
| MEDLINE | ID: mdl-37108880
3.
Global Cutaneous Mucormycosis: A Systematic Review.
J Fungi (Basel)
; 8(2)2022 Feb 16.
Article
in English
| MEDLINE | ID: mdl-35205948
4.
In vivo fitness of carbapenem-resistant Acinetobacter baumannii strains in murine infection is associated with treatment failure in human infections.
Clin Microbiol Infect
; 28(1): 73-78, 2022 Jan.
Article
in English
| MEDLINE | ID: mdl-33984488
5.
Epidemiology and Diagnosis of Mucormycosis: An Update.
J Fungi (Basel)
; 6(4)2020 Nov 02.
Article
in English
| MEDLINE | ID: mdl-33147877
6.
Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial.
Lancet Infect Dis
; 18(4): 391-400, 2018 04.
Article
in English
| MEDLINE | ID: mdl-29456043
7.
Rare fungal infectious agents: a lurking enemy.
F1000Res
; 6: 1917, 2017.
Article
in English
| MEDLINE | ID: mdl-29152230
8.
Early changes of procalcitonin may advise about prognosis and appropriateness of antimicrobial therapy in sepsis.
J Crit Care
; 26(3): 331.e1-7, 2011 Jun.
Article
in English
| MEDLINE | ID: mdl-20869839
9.
Expiratory effort enhancement and peak expiratory flow in humans.
Eur J Appl Physiol
; 94(1-2): 11-6, 2005 May.
Article
in English
| MEDLINE | ID: mdl-15627207
Results
1 -
9
de 9
1
Next >
>>